New drug aims to reduce bleeding episodes in hemophilia patients
NCT ID NCT07416526
First seen Feb 28, 2026 · Last updated Apr 21, 2026 · Updated 5 times
Summary
This study is testing whether a new preventive drug called NXT007 works better than the current standard treatment (Factor VIII) at reducing bleeding episodes in people with hemophilia A. Researchers will enroll 126 participants aged 12 and older who have moderate to severe hemophilia A and are already using preventive Factor VIII treatment. The main goal is to see which treatment leads to fewer bleeds requiring treatment over the study period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nara Medical University Hospital
RECRUITINGKashihara-shi, Nara, 634-8522, Japan
-
Tokyo Medical University Hospital
RECRUITINGShinjuku-Ku, Tokyo, 160-0023, Japan
Conditions
Explore the condition pages connected to this study.